History of Antibody Therapy for Non-Hodgkin's Lymphoma

Seminars in Oncology

Volumn 30, Issue 6 SUPPL. 17, 2003, Pages 1-5

  Forero, Andres ^a,b   LoBuglio, Albert F ^a  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIBODY; CD20 ANTIGEN; DENILEUKIN DIFTITOX; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; IMMUNOTOXIN; MEMBRANE ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 1F5 I 131; MONOCLONAL ANTIBODY B1 I 131; RITUXIMAB; TOSITUMOMAB I 131; TRASTUZUMAB; UNCLASSIFIED DRUG; YTTRIUM 90;

ANTIBODY ENGINEERING; ANTIGEN BINDING; B CELL LYMPHOMA; B CELL NONHODGKIN LYMPHOMA; BIOTECHNOLOGY; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; FOOD AND DRUG ADMINISTRATION; HEMATOLOGIC MALIGNANCY; HISTORY; HUMAN; HYBRIDOMA; ISOTOPE LABELING; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; RECOMBINANT DNA TECHNOLOGY; REVIEW; TARGET CELL DESTRUCTION;

EID: 0346098179     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2003.10.002     Document Type: Article

References (36)

1. Zevalin (ibritumomab tiuxetan) prescribing information: Cambridge, MA, Biogen Idec Inc, 2002
2. von Behring E, Kitasato S: Über das Zustandekommen der Diphtherie-Immunität und der Tetanus-Immunität bei Thieren. Dtsch Med Wochenschr 16:1113-1114, 1890
3. Ehrlich P: The Croonian Lecture: On immunity with special reference to cell life. Proc R Soc Lond 66:424-448, 1900
4. Hericourt J, Richet C: Physiologie pathologique-de la serotherapie dans le traitement du cancer. Comptes Rendu Hebd Seanc Acad Sci 120:948-950, 1895
5. Hericourt J, Richet C: Physiologie pathologique-de la serotherapie dans le traitement du cancer. Comptes Rendu Hebd Seanc Acad Sci 121:567-569, 1895
6. Laszlo J, Buckley CE III, Amos DB: Infusion of isologous immune plasma in chronic lymphocytic leukemia. Blood 31: 104-110, 1968
7. Lindstrom GA: An experimental study of myelotoxic sera. Therapeutic attempts in myeloid leukaemia. Acta Med Scandinavia 22:1-169, 1929
8. Köhler G, Milstein C: Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495-497, 1975
9. Tonegawa S: Somatic generation of antibody diversity. Nature 302:575-581, 1983
10. Alt FW, Oltz EM, Young F, et al: VDJ recombination. Immunol Today 13:306-314, 1992
11. Ritz J, Schlossman SF: Utilization of monoclonal antibodies in the treatment of leukemia and lymphoma. Blood 59:1-11, 1982
12. Nadler LM, Stashenko P, Hardy R, et al: Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res 40:3147-3154, 1980
13. Miller RA, Maloney DG, Warnke R, et al: Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med 306:517-522, 1982
14. Vuist WM, Levy R, Maloney DG: Lymphoma regression induced by monoclonal anti-idiotypic antibodies correlates with their ability to induce Ig signal transduction and is not prevented by tumor expression of high levels of bcl-2 protein. Blood 83:899-906, 1994
15. Davis TA, Maloney DG, Czerwinski D, et al: Anti-idiotype antibodies can induce long-term complete remissions in non-Hodgkin's lymphoma without eradicating the malignant clone. Blood 92:1184-1190, 1998
16. Tedder TF, Boyd AW, Freedman AS, et al: The B cell surface molecule B1 is functionally linked with B cell activation and differentiation. J Immunol 135:973-979, 1985
17. 2+ conductance found constitutively in B lymphocytes. J Cell Biol 121:1121-1132, 1993
18. Anderson KC, Bates MP, Slaughenhoupt BL, et al: Expression of human B cell-associated antigens on leukemias and lymphomas: A model of human B cell differentiation. Blood 63:1424-1433, 1984
19. Almasri NM, Duque RE, Iturraspe J, et al: Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemia. Am J Hematol 40:259-263, 1992
20. Press OW, Appelbaum F, Ledbetter JA, et al: Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood 69:584-591, 1987
21. 131I-anti-B1 (anti-CD20) antibody. N Engl J Med 329:459-465, 1993
22. Kaminski MS, Zasadny KR, Francis IR, et al: Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol 14:1974-1981, 1996
23. 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: Updated results and long-term follow-up of the University of Michigan experience. Blood 96:1259-1266, 2000
24. Reff ME, Carner K, Chambers KS, et al: Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83:435-445, 1994
25. Maloney DG, Liles TM, Czerwinski D, et al: Phase 1 clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 84:2457-2466, 1994
26. Maloney DG, Grillo-López AJ, Bodkin DJ, et al: IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 15:3266-3274, 1997
27. Maloney DG, Grillo-Lopez AJ, White CA, et al: IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90:2188-2195, 1997
28. Coiffier B, Haioun C, Ketterer N, et al: Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study. Blood 92:1927-1932, 1998
29. McLaughlin P, Grillo-Lopez AJ, Link BK, et al: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825-2833, 1998
30. Press OW, Farr AG, Borroz KI, et al: Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies. Cancer Res 49:4906-4912, 1989
31. Witzig TE, Gordon LI, Cabanillas F, et al: Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 20:2453-2463, 2002
32. Witzig TE, Flinn LW, Gordon LI, et al: Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 20:3262-3269, 2002
33. Wiseman GA, Gordon LI, Multani PS, et al: Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: A phase II multicenter trial. Blood 99:4336-4342, 2002
34. 131I tositumomab) prescribing information: Corixa Corporation, Seattle, WA, 2003
35. Kaminski MS, Zelenetz AD, Press OW, et al: Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 19:3918-3928, 2001
36. Horning SJ, Lucas JB, Younes A, et al: Iodine-131 tositumomab for non-Hodgkin's lymphoma (NHL) patients who progressed after treatment with rituximab: Results of a multicenter phase II study. Blood 96:508a, 2000 (abstr)